Phase II trial of daratumumab, bortezomib, lenalidomide and dexamethasone in high-risk smoldering multiple myeloma

被引：0
|
作者：
Nadeem, Omar [1 ]
Redd, Robert [1 ]
Mo, Clifton [1 ]
Laubach, Jacob [1 ]
Richardson, Paul G. [1 ]
Prescott, Julia [1 ]
Marto, Marjorie [1 ]
Davie, Christine [1 ]
Ricciardi, Caroline [1 ]
Murphy, Elizabeth [1 ]
Bertoni, Meredith [1 ]
Choden, Dechen [1 ]
Magidson, Sophie [1 ]
Sheehan, Brian [1 ]
Shrestha, Hira [1 ]
Sperling, Adam S. [1 ]
O'Donnell, Elizabeth K. [2 ]
Ghobrial, Irene M. [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-099
引用
收藏
页码：S89 / S89
页数：1
相关论文
共 50 条
  • [31] A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: First Report of Efficacy and Safety
    Nadeem, Omar
    Redd, Robert
    Stampleman, Laura V.
    Matous, Jeffrey V.
    Yee, Andrew J.
    Zonder, Jeffrey A.
    Kin, Andrew
    Rosenblatt, Jacalyn
    Bustoros, Mark
    Prescott, Julia
    Savell, Alexandra
    Guimond, Kathleen
    Frey, Erin
    Styles, Rachel
    Bielawski, Adrienne
    Boehner, Cody J.
    Kham, Nang
    Sperling, Adam S.
    Bianchi, Giada
    Laubach, Jacob P.
    Castillo, Jorge J.
    Munshi, Nikhil C.
    Anderson, Kenneth C.
    Richardson, Paul G.
    Trippa, Lorenzo
    Ghobrial, Irene M.
    BLOOD, 2019, 134
  • [32] OPTIMUM/MUKnine trial: Extended post-ASCT consolidation with Daratumumab, Bortezomib, Lenalidomide and dexamethasone for Ultra-high risk myeloma
    Jenner, Matthew
    Hall, Andrew
    Smith, Isabelle
    de Tute, Ruth
    Roberts, Sadie
    Pratt, Guy
    Drayson, Mark
    Owen, Roger
    Brown, Sarah
    Kaiser, Martin
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 18 - 19
  • [33] Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial
    Usmani, Saad Z.
    Hoering, Antje
    Ailawadhi, Sikander
    Sexton, Rachael
    Lipe, Brea
    Hita, Sandi Fredette
    Valent, Jason
    Rosenzweig, Michael
    Zonder, Jeffrey A.
    Dhodapkar, Madhav
    Callander, Natalie
    Zimmerman, Todd
    Voorhees, Peter M.
    Durie, Brian
    Rajkumar, S. Vincent
    Richardson, Paul G.
    Orlowski, Robert Z.
    LANCET HAEMATOLOGY, 2021, 8 (01): : E45 - E54
  • [34] Smoldering multiple myeloma associated with a acquired von Willebrand syndrome, successfully treated by daratumumab, lenalidomide and dexamethasone
    Iarossi, Michael
    Vekemans, Marie-Christiane Madeleine
    Weynants, Nicolas
    Hermans, Cedric
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S276 - S276
  • [35] Acquired von Willebrand Syndrome Associated with a Smoldering Multiple Myeloma, Successfully Treated by Daratumumab, Lenalidomide, and Dexamethasone
    Iarossi, Michael
    Vekemans, Marie-Christiane Madeleine
    Weynants, Nicolas
    Hermans, Cedric
    ACTA HAEMATOLOGICA, 2024,
  • [36] Phase I/II study of bortezomib, lenalidomide, and dexamethasone treatment for relapsed and refractory multiple myeloma
    Yasuo Mori
    Ilseung Choi
    Goichi Yoshimoto
    Tsuyoshi Muta
    Satoshi Yamasaki
    Kazuki Tanimoto
    Tomohiko Kamimura
    Hiromi Iwasaki
    Ryosuke Ogawa
    Koichi Akashi
    Toshihiro Miyamoto
    International Journal of Hematology, 2020, 111 : 673 - 680
  • [37] Phase I/II study of bortezomib, lenalidomide, and dexamethasone treatment for relapsed and refractory multiple myeloma
    Mori, Yasuo
    Choi, Ilseung
    Yoshimoto, Goichi
    Muta, Tsuyoshi
    Yamasaki, Satoshi
    Tanimoto, Kazuki
    Kamimura, Tomohiko
    Iwasaki, Hiromi
    Ogawa, Ryosuke
    Akashi, Koichi
    Miyamoto, Toshihiro
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (05) : 673 - 680
  • [38] Daratumumab, Bortezomib, and Dexamethasone for Previously Treated Multiple Myeloma
    Huang, Shang-Xiao
    Luo, Peng-Hui
    Wang, Han-Lei
    Mo, Dun-Chang
    Huang, Jian-Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (14) : 2667 - 2668
  • [39] Venetoclax in Combination With Bortezomib, Dexamethasone, and Daratumumab for Multiple Myeloma
    Rahbari, Kian J.
    Nosrati, Jason D.
    Spektor, Tanya M.
    Berenson, James R.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (09): : E339 - E343
  • [40] Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma
    Plesner, Torben
    Arkenau, Hendrik-Tobias
    Gimsing, Peter
    Krejcik, Jakub
    Lemech, Charlotte
    Minnema, Monique C.
    Lassen, Ulrik
    Laubach, Jacob P.
    Palumbo, Antonio
    Lisby, Steen
    Basse, Linda
    Wang, Jianping
    Sasser, A. Kate
    Guckert, Mary E.
    de Boer, Carla
    Khokhar, Nushmia Z.
    Yeh, Howard
    Clemens, Pamela L.
    Ahmadi, Tahamtan
    Lokhorst, Henk M.
    Richardson, Paul G.
    BLOOD, 2016, 128 (14) : 1821 - 1828
12345